Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Blackthorn Therapeutics Inc.
Headquarters: San Francisco, CA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Nov 6, 2024
Product Development
Two upcoming readouts could shape the market for κ-opioid antidepressants
Emerging class could find niche among patients whose major depressive disorder includes symptoms of anhedonia
BioCentury | Jan 31, 2024
Product Development
The path to precision neuropsychiatry: J&J’s perspective
From subjective symptoms to objective metrics to biological signatures, neuroscience head Bill Martin paints a trajectory of psychiatry’s path ahead
BioCentury | Oct 7, 2021
Emerging Company Profile
Arch-backed Neumora: using data tools for precision neuroscience
Deep-pocketed Arch, partner Amgen back Neumora’s eight-program pipeline in neuroscience
BioCentury | Aug 20, 2020
Management Tracks
Shao out as Sorrento CFO; plus changes at Kronos, Rome and Alveo
Sorrento Therapeutics Inc. (NASDAQ:SRNE) terminated Jiong Shao as EVP and CFO. He is succeeded as CFO by Najjam Asghar, who is the company’s chief accounting officer. Sorrento did not
BioCentury | Oct 23, 2019
Company News
Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio
BioCentury | Aug 22, 2019
Tools & Techniques
Digital makes its mark on cognition
Digital biomarkers that bring objectivity to clinical assessment of cognition could be just around the corner
BioCentury | Jun 19, 2019
Financial News
June 19 Financial Quick Takes: Stoke rises after IPO; plus Polaris, Woodford, follow-ons
BioCentury | Jun 13, 2019
Finance
With $76M series B, BlackThorn looks to build out neurobehavioral platform
How BlackThorn rebounded from a January clinical setback to raise $76 million to develop its targeted therapies for neurobehavioral disorders
Items per page:
1 - 10 of 27